Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly losses of $(2.25) per share. This is a 97.41 percent increase over losses...
Effective as of Commencement of Trading on August 15, 2025Vyome Therapeutics, Inc., a clinical-stage healthcare company targeti...
Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on ...
https://reshapelifesciences.gcs-web.com/news-releases/news-release-details/reshape-lifesciencesr-granted-us-patent-related-intr...
The patent, related to the Company's application 18/241,151 and notice of allowance received in April, covers claims for an...
